Dr. Kudva's research focuses on improving existing treatments and developing novel therapies for patients with type 1 diabetes. Our team in the Artificial Pancreas Laboratory at Mayo Clinic is especially interested in developing an effective artificial pancreas system, but our research spans a wide breadth of novel treatment and care for both adults and children with diabetes.
Current ongoing research studies and trials in our lab include:
- The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3). The objective of this diabetes research study is to assess the efficacy and safety of a closed-loop system (t:slim X2 with Control-IQ Technology) in a large randomized controlled trial.
- Multi-Center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients with Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home. The main goal of this diabetes research study is to evaluate the safety and efficacy of 670G (an insulin pump system) compared to participants with a continuous subcutaneous insulin infusion (CSII), a sensor-augmented insulin pump (SAP) and multiple daily injections (MDI).
- Harnessing Non-Glucose Feedback Signals for Automatic Glucose Control in Type 1 Diabetes: Confronting Exercise-Safety and Stress-Aware Control. The goal of this research project is to further develop continuous glucose monitors to better measure and predict glucose levels when patients exercise or undergo physical exertion.
- Wireless Innovation for Seniors with Diabetes Mellitus (WISDM). The main objective of this study is to evaluate the safety and efficacy of continuous glucose monitoring in older adults with type 1 diabetes using multiple daily injections and continuous subcutaneous insulin infusion.